Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-5: loncastuximab tesirine + rituximab versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
jRCT2011230028Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of loncastuximab tesirine, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Progression-free survival. Started Oct 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirinerituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT2011230028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230028.